Annexon, Inc. (ANNX)Healthcare | Biotechnology | Brisbane, United States | NasdaqGS
3.74 USD
-0.09
(-2.347%) ⇩
(Oct. 14, 2026, 12:53 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:58 a.m. EDT
The long-term outlook is severely compromised by a brutal five-year trajectory where the stock has lost nearly 89% of its value, driven by four consecutive years of negative annual returns. Despite a recent bounce in 2024, the business fundamentals remain broken with negative earnings, negative free cash flow, and a return on equity of -105%. The balance sheet, while currently liquid, supports a company burning cash with no dividend to cushion the blow. The short-term rating is merely slightly bearish because the recent price action shows some stabilization near the 50-day average, but the heavy put volume and lack of institutional support suggest continued weakness. The massive upside potential cited by analysts relies entirely on a binary biotech event that hasn't happened yet; until then, the risk-reward profile is unfavorable. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.134964 |
| AutoARIMA | 0.135470 |
| MSTL | 0.136141 |
| AutoTheta | 0.140317 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 78.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.108 |
| Excess Kurtosis | -1.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.249 |
| Market Cap | 709,025,984 |
| Forward P/E | -3.44 |
| Beta | 1.33 |
| Website | https://www.annexonbio.com |
As of Oct. 10, 2026, 2:58 a.m. EDT: Speculators are positioning heavily for downside protection with massive open interest in deep out-of-the-money puts (strikes $2.00 and $3.00) expiring in December 2026, suggesting a fear of a significant drop. Conversely, there is aggressive call buying at strikes $8.00 and $10.00 for January 2027, indicating a speculative bet on a massive recovery or biotech trial success. The implied volatility is skewed significantly higher for the downside strikes in the near term, reflecting asymmetric risk pricing.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.25986838 |
| Address1 | 1,400 Sierra Point Parkway |
| Address2 | Building C Suite 200 |
| All Time High | 38.01 |
| All Time Low | 1.285 |
| Ask | 4.87 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 3,189,320 |
| Average Daily Volume3 Month | 3,027,173 |
| Average Volume | 3,027,173 |
| Average Volume10Days | 3,189,320 |
| Beta | 1.328 |
| Bid | 2.86 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.066 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.74 |
| Current Ratio | 5.529 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.85 |
| Day Low | 3.7 |
| Debt To Equity | 13.249 |
| Display Name | Annexon |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -208,388,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.598 |
| Enterprise Value | 541,496,064 |
| Eps Current Year | -1.05138 |
| Eps Forward | -1.08661 |
| Eps Trailing Twelve Months | -1.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 636 9773 |
| Fifty Day Average | 4.6026 |
| Fifty Day Average Change | -0.8626001 |
| Fifty Day Average Change Percent | -0.18741582 |
| Fifty Two Week Change Percent | 25.98684 |
| Fifty Two Week High | 7.18 |
| Fifty Two Week High Change | -3.4399998 |
| Fifty Two Week High Change Percent | -0.47910863 |
| Fifty Two Week Low | 2.54 |
| Fifty Two Week Low Change | 1.2 |
| Fifty Two Week Low Change Percent | 0.47244096 |
| Fifty Two Week Range | 2.54 - 7.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,595,597,400,000 |
| Float Shares | 163,760,352 |
| Forward Eps | -1.08661 |
| Forward P E | -3.4418974 |
| Free Cashflow | -115,986,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 92 |
| Fullday Change | -0.089999914 |
| Fullday Change Percent | -2.3474157 |
| Fullday Price | 3.74 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00438 |
| Held Percent Institutions | 1.0312899 |
| Implied Shares Outstanding | 189,579,134 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. |
| Long Name | Annexon, Inc. |
| Market | us_market |
| Market Cap | 709,025,984 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_279883519 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -202,668,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 733,671,248 |
| Number Of Analyst Opinions | 7 |
| Open | 3.79 |
| Operating Cashflow | -193,032,992 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 650 822 5500 |
| Previous Close | 3.83 |
| Price Eps Current Year | -3.5572295 |
| Price Hint | 4 |
| Price To Book | 3.5084429 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.437 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -0.089999914 |
| Regular Market Change Percent | -2.3474157 |
| Regular Market Day High | 3.85 |
| Regular Market Day Low | 3.7 |
| Regular Market Day Range | 3.7 - 3.85 |
| Regular Market Open | 3.79 |
| Regular Market Previous Close | 3.83 |
| Regular Market Price | 3.74 |
| Regular Market Time | 1,791,996,837 |
| Regular Market Volume | 1,678,413 |
| Return On Assets | -0.51542 |
| Return On Equity | -1.05261 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 189,579,134 |
| Shares Percent Shares Out | 0.1688 |
| Shares Short | 32,009,914 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 32,094,286 |
| Short Name | Annexon, Inc. |
| Short Percent Of Float | 0.17870001 |
| Short Ratio | 9.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANNX |
| Target High Price | 27.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 15.42857 |
| Target Median Price | 14.0 |
| Total Cash | 209,243,008 |
| Total Cash Per Share | 1.104 |
| Total Debt | 24,651,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.32085 |
| Two Hundred Day Average Change | -1.5808499 |
| Two Hundred Day Average Change Percent | -0.29710478 |
| Type Disp | Equity |
| Volume | 1,678,413 |
| Website | https://www.annexonbio.com |
| Zip | 94,005 |